Business Context and Reporting Period
Company: Achieve Life Sciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: October 1, 2018
Event: Entry into a Material Definitive Agreement for a Registered Direct Offering and concurrent Private Placement.
Key Financial Metrics and Transaction Details
- Shares Offered: 1,789,258 shares of common stock.
- Offering Price: $3.1445 per share.
- Gross Proceeds: Approximately $5.6 million (before fees and expenses).
- Placement Agent Fee: 8% of gross proceeds.
- Expense Reimbursement: Up to $60,000.
- Warrants Issued: 894,626 warrants (50% of shares sold).
- Warrant Terms: Exercise price of $3.1445; exercisable immediately; expire on the fifth anniversary.
- Use of Proceeds: Funding development of cytisine, working capital, and general corporate purposes.
Material Changes and Unusual Items
This filing reports a specific capital raise event rather than periodic financial performance. The material change is the execution of a Securities Purchase Agreement and Placement Agency Agreement on October 1, 2018. The filing does not provide comparative financial data (revenue, profit, cash flow, or margins) against prior periods as it is a transactional report, not a quarterly or annual earnings report.
Guidance, Outlook, and Risks
- Management Commentary: Proceeds are explicitly designated to fund the development of cytisine.
- Beneficial Ownership Limitation: Warrant holders are restricted from exercising if it would result in beneficial ownership exceeding 4.99% of outstanding shares (increasable to 9.99% with notice).
- Risks/Contingencies: The offering is subject to customary conditions to closing and representations and warranties. The filing incorporates by reference the full legal agreements for detailed risk terms.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting the 8% fee and expenses.
- Confirm the specific milestones for the "cytisine" development program funded by these proceeds.
- Review the full text of the Placement Agency Agreement (Exhibit 1.1) and Securities Purchase Agreement (Exhibit 10.1) for termination provisions and specific conditions to closing.
- Monitor the impact of the 1,789,258 new shares and potential warrant exercises on existing shareholder dilution.